Novel LncRNA OXCT1-AS1 indicates poor prognosis and contributes to tumorigenesis by regulating miR-195/CDC25A axis in glioblastoma

Abstract Background Long noncoding RNAs (lncRNAs) contribute to multiple biological processes in human glioblastoma (GBM). However, identifying a specific lncRNA target remains challenge. In this study, bioinformatics methods and competing endogenous RNA (ceRNA) network regulatory rules were used identify GBM-related lncRNAs revealed that OXCT1 antisense 1 (OXCT1-AS1) is potential therapeutic for the treatment of glioma. Methods Based on Gene Expression Omnibus (GEO) dataset, we identified differential lncRNAs, microRNAs mRNAs constructed an lncRNA-associated ceRNA network. The novel OXCT1-AS1 was proposed function as ceRNA, its miRNAs predicted through database LncBase Predicted v.2. expression patterns glioma normal tissue samples measured. effect cells checked using Cell Counting Kit 8 assay, cell colony formation Transwell assay flow cytometry vitro. dual-luciferase activity performed investigate mechanism Finally, orthotopic mouse models created evaluate influence tumour growth vivo. Results it found upregulated both Cancer Genome Atlas (TCGA) GBM patients samples, high poor prognosis. Suppressing significantly decreased proliferation inhibited migration invasion. We further investigated may act miR-195 enhance CDC25A promote progression. knocking down notably attenuated severity Conclusion inhibits progression by regulating miR-195-5p/CDC25A axis marker treatment.